Rebecca Moss, MD
Assistant Professor of Medicine, Medical Oncology
Rutgers Cancer Institute of New Jersey
Assistant: Kim Williams
Research Program Alignments
- Clinical Investigations Program
Membership Type: Associate - CCSG
- Colon Cancer
- Hepatocellular Cancer
- Esophageal Cancer
- C-Met Receptor
Robert Fine, Anthony Gulati, Benjamin Krantz, Rebecca A. Moss, Stephen Schreibman, Dawn Tsushima, Kelley Mowatt, Richard Dinnen, Yuehua Mao, Beth Schrope, John Allendorf, James Lee, William Sherman, John Chabot; “Capecitabine and Temozolomide (CAPTEM) for Metastatic, Well-Differentiated Neuroendocrine Cancers: The Pancreas Center at Columbia University Experience” Cancer Chemotherapy and Pharmacology published online 31 January 2013.
Ravi Salgia, Premal Patel, Anshu Vashishtha, Wei Yu, Shuang Bai, Amy Peterson and Rebecca A. Moss; “Phase I Dose-Escalation Study of Onartuzumab as a single agent and in combination with Bevacizumab in patients with advanced solid malignancies,” Clin Cancer Res. 2014 Feb 3. [Epub ahead of print]
Gazala Khan, Rebecca A. Moss, Fadi Braiteh,Marc Saltzman, “Regorafenib for the treatment of metastatic colorectal cancer: a review of the CORRECT trial and proactive strategies for optimal patient management” Cancer Management and Research 2014:6 1–11
Rebecca A. Moss, Clifton Lee; “Current and emerging therapies for the treatment of pancreatic cancer”; OncoTargets and Therapy, Volume 2010:3 pages 111-127, 2010.
Biren Saraiya, Rashmi Chugh R, Vasiliki Karantza, Janice Mehnert, Rebecca A. Moss, Nelli Savkina, Mark N. Stein, Lawrence H. Baker, Thomas Chenevert, Elizabeth A. Poplin.; “Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors”; Invest New Drugs, 2010 Feb;30(1):258-65. Epub 2010 Aug 10. 2010.
Janice Mehnert, Antionette Tan, Rebecca A. Moss, Elizabeth Poplin, Mark N. Stein, Mika Sovak, Kelly Levinson, Hongxia Lin, Michael Kane, Murugesan Gounder, Yong Lin, Weichung Joe Shih, Eileen White, Eric H. Rubin, , Vassiliki Karantza; “Rationally designed treatment for solid tumors with MAPK pathway activation: A Phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach”; Molecular Cancer Therapeutics, 2011. [Epub ahead of print]
Howard Burris, III, Afshin Dowlati, Rebecca A. Moss, Jeffrey Infante, Suzanne Jones, David Spigal, Kelly Levinson, Diana Lindquist, Shelby Gainer, Mohammed Dar, A Benjamin Suttle, Howard Ball, and Antoinette Tan; “Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors”; Molecular Cancer Therapeutics, 2012. Epub ahead of print]
Rebecca A. Moss, Dirk Moore, Mary Mulcahy, Kenneth Nahum, Biren Saraiya, Simantini Eddy, Martin Kleber, Elizabeth Poplin; A Multi-Institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer; Gastrointestinal Cancer Research, Volume 5(3):77-83, 2012.